{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:15:53Z","timestamp":1787019353989,"version":"build-2736575974"},"reference-count":119,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    Multiple myeloma (MM) is a B-cell malignancy involving monoclonal plasma cells that produce nonfunctional immunoglobulins. It is still incurable due to de novo or acquired resistance of malignant cells to standard chemotherapies. Thus, understanding the mechanism of therapeutic resistance is essential to develop better interventions and identifying new therapeutic targets. MM is a heterogeneous disease characterized by complex genetic alterations, which are critical for prognostic stratification. Due to the heterogeneity and clinical challenges associated with MM, there remains a critical need for novel biomarkers to improve both early diagnosis and prognostic accuracy. Antioxidants participate in protecting cancer cells from the damaging effects of oxidative stress by neutralizing reactive oxygen species. These molecules may have their own role in myeloma progression and drug resistance. However, studies reported contradictory ideas regarding the levels and roles of antioxidants in MM. The main aim of this review is to conceptualize the diagnostic, prognostic, and therapeutic significance of common antioxidants for MM. The most common antioxidant systems discussed in this study were DJ-1, glutathione, thioredoxin, and superoxide dismutase. The review revealed that antioxidants are overexpressed in myeloma cells compared to normal plasma cells. This excess expression of antioxidants increases tumor cells\u2019 survival and their chemoresistance leads to poor prognosis and short survival of myeloma patients. Thus, antioxidants and their synthesis pathways may have a promising prognostic, diagnostic, and therapeutic role in MM. Vitamin C (ascorbic acid), on the other hand, has a two-faced role in cancer, including MM. It can function as an antioxidant (increase myeloma cell resistance to chemotherapy) or pro-oxidant (enhance the therapeutic effect of myeloma drugs), depending on its dose and route of administration. Pharmacological (ultra-high) doses of vitamin C administered intravenously may act as a pro-oxidant that can selectively kill myeloma cells by elevating the cellular labile iron pool and generating extracellular H\n                    <jats:sub>2<\/jats:sub>\n                    O\n                    <jats:sub>2<\/jats:sub>\n                    .\n                  <\/jats:p>","DOI":"10.1177\/20406207261419810","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:30:48Z","timestamp":1771497048000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2540-2602","authenticated-orcid":false,"given":"Sintayehu","family":"Admas","sequence":"first","affiliation":[{"name":"Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisrat Birke","family":"Teketelew","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigusie","family":"Alemu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyusira","family":"Marelgn","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunohematology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, Mizan Tepi University, Mizan Tepi, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemataw","family":"Gelaw","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"27","key":"e_1_3_4_2_2","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke C","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, et al. The diagnosis and treatment of multiple myeloma. Dtsch \u00c4rztebl Int 2016; 113(27\u201328): 470.","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051033"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030396"},{"issue":"6","key":"e_1_3_4_6_2","first-page":"373","article-title":"Multiple myeloma: diagnosis and treatment","volume":"95","author":"Michels TC","year":"2017","unstructured":"Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Phys 2017; 95(6): 373\u2013383.","journal-title":"Am Fam Phys"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07833-5"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2015.1136038"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118852"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.11.002"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112357"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03756-3"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07066.x"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102411"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.07.017"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.12"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101310"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040439"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007653"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.120144"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.12.004"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.45"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-016-1303-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-6583-5_4"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00994"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-6583-5_13"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","unstructured":"Raninga PV Di Trapani G Tonissen KF. The multifaceted roles of DJ-1 as an antioxidant. In: Ariga H Iguchi-Ariga SMM (eds.) DJ-1\/PARK7 Protein: Parkinson\u2019s disease cancer and oxidative stress-induced diseases (Advances in experimental medicine and biology book 1037). Singapore: Springer Nature 2017 pp. 67\u201387.","DOI":"10.1007\/978-981-10-6583-5_6"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2017.09.008"},{"key":"e_1_3_4_29_2","volume-title":"Antioxidant systems, thioredoxin and DJ-1: novel therapeutic targets in multiple myeloma","author":"Raninga PV.","year":"2016","unstructured":"Raninga PV. Antioxidant systems, thioredoxin and DJ-1: novel therapeutic targets in multiple myeloma. Phd Dissertation, Griffith University, Australia, 2016."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes15030387"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.01.029"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3795"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2021.1913400"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.722646"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.086"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2023.11.001"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0772"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.02.011"},{"issue":"5","key":"e_1_3_4_39_2","first-page":"1033","article-title":"Enhancement of ascorbate cytotoxicity by chelation with ferrous ions through prolonged duration of the action","volume":"6","author":"Miwa N","year":"1986","unstructured":"Miwa N, Yamazaki H, Ikari Y. Enhancement of ascorbate cytotoxicity by chelation with ferrous ions through prolonged duration of the action. Anticancer Res 1986; 6(5): 1033\u20131036.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715762.2024.2320396"},{"issue":"3","key":"e_1_3_4_41_2","first-page":"809","article-title":"High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer","volume":"29","author":"Ohno S","year":"2009","unstructured":"Ohno S, Ohno Y, Suzuki N, et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009; 29(3): 809\u2013815.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506390102"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0135-7"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu12051501"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2021.02.126"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.014"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041060"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.07.079"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu11050977"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14030221"},{"key":"e_1_3_4_51_2","volume-title":"Targeting thioredoxin reductase in multiple myeloma","author":"Sze JH.","year":"2019","unstructured":"Sze JH. Targeting thioredoxin reductase in multiple myeloma. PhD Dissertation. Griffith University, Australia, 2019."},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(00)00590-4"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051256"},{"issue":"20","key":"e_1_3_4_54_2","first-page":"6928","article-title":"Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS\/DJ-1 and RhoGDI\u03b1","volume":"63","author":"MacKeigan JP","year":"2003","unstructured":"MacKeigan JP, Clements CM, Lich JD, et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS\/DJ-1 and RhoGDI\u03b1. Cancer Res 2003; 63(20): 6928\u20136934.","journal-title":"Cancer Res"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20159"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.08.046"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091432"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.207134"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2010.04.002"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.56"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040439"},{"issue":"3","key":"e_1_3_4_62_2","first-page":"2153","article-title":"Identification of glutathione S\u2011transferase \u03c0 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling","volume":"19","author":"Zhao J","year":"2020","unstructured":"Zhao J, Wang M, He P, et al. Identification of glutathione S\u2011transferase \u03c0 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling. Oncol Lett 2020; 19(3): 2153\u20132162.","journal-title":"Oncol Lett"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.07.004"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31248-w"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215649"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.11.012"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.190"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013805"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.53293\/jasn.2022.4509.1117"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23387"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20112019"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902802323"},{"key":"e_1_3_4_73_2","first-page":"5401","article-title":"The death-associated protein kinase 2 (DAPK2) is transcriptionally regulated by KLF6\/E2F1 transcription factors and green tea extract","volume":"67","author":"Britschgi A","year":"2007","unstructured":"Britschgi A, Trinh E, Rizzi M, et al. The death-associated protein kinase 2 (DAPK2) is transcriptionally regulated by KLF6\/E2F1 transcription factors and green tea extract. Cancer Res 2007; 67(9_Supplement): 5401.","journal-title":"Cancer Res"},{"key":"e_1_3_4_74_2","volume-title":"The role of Klf9 in cell stress-induced cell death in normal cells and in the therapeutic response of multiple myeloma cells to proteasome inhibitors","author":"Emily F.","year":"2017","unstructured":"Emily F. The role of Klf9 in cell stress-induced cell death in normal cells and in the therapeutic response of multiple myeloma cells to proteasome inhibitors. PhD Dissertation, State University of New York at Buffalo, USA, 2017."},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.12.001"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3400"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015628"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2020.34.s1.03959"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.TM117.000257"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03536-5"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409635102"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.09.017"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399808"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds131"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607260103"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.82"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1736"},{"issue":"4","key":"e_1_3_4_88_2","first-page":"403","article-title":"Thioredoxin signaling pathways in cancer","volume":"38","author":"Zhang J","year":"2023","unstructured":"Zhang J, Li X, Zhao Z, et al. Thioredoxin signaling pathways in cancer. Antioxid Redox Signal 2023; 38(4): 403\u2013424.","journal-title":"Antioxid Redox Signal"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.06.001"},{"issue":"17","key":"e_1_3_4_90_2","first-page":"5089","article-title":"The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1\u03b1 protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis","volume":"62","author":"Welsh SJ","year":"2002","unstructured":"Welsh SJ, Bellamy WT, Briehl MM, et al. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1\u03b1 protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002; 62(17): 5089\u20135095.","journal-title":"Cancer Res"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1097\/PN9.0000000000000083"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.83"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox6040094"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00574"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.50"},{"key":"e_1_3_4_96_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137284"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2016.01.007"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003820"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23387"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16503"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-017-0169-9"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05592-w"},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2012.721156"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/tox.20737"},{"key":"e_1_3_4_105_2","first-page":"5749","article-title":"Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells","volume":"10","author":"Zeng J","year":"2017","unstructured":"Zeng J, Liu T, Zheng Y, et al. Diallyl trisulfide inhibits proliferation and promotes apoptosis of side population cells in multiple myeloma cells. Int J Clin Exp Med 2017; 10: 5749\u20135756.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/em.20431"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092287"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.08.031"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0575-7"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28149"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.10.3685"},{"issue":"1","key":"e_1_3_4_112_2","article-title":"Pro- and antioxidant effects of vitamin C in cancer in correspondence to its dietary and pharmacological concentrations","volume":"2019","author":"Pawlowska E","year":"2019","unstructured":"Pawlowska E, Szczepanska J, Blasiak J. Pro- and antioxidant effects of vitamin C in cancer in correspondence to its dietary and pharmacological concentrations. Oxid Med Cell Longev 2019; 2019(1): 7286737.","journal-title":"Oxid Med Cell Longev"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.032"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0503"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox7070092"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2017.08.004"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.989000"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1812"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2564.2564"},{"issue":"3","key":"e_1_3_4_120_2","first-page":"696","article-title":"Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma","volume":"18","author":"Allegra A","year":"2021","unstructured":"Allegra A, Rizzo V, Innao V, et al. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. Arch Med Sci 2021; 18(3): 696.","journal-title":"Arch Med Sci"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261419810","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261419810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:13Z","timestamp":1777591093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261419810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":119,"alternative-id":["10.1177\/20406207261419810"],"URL":"https:\/\/doi.org\/10.1177\/20406207261419810","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20406207261419810"}}